BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/19/2017 6:44:00 PM | Browse: 1002 | Download: 1407
Publication Name World Journal of Gastroenterology
Manuscript ID 31541
Country/Territory United States
Received
2016-11-24 11:57
Peer-Review Started
2016-11-25 11:48
To Make the First Decision
2016-12-19 09:54
Return for Revision
2016-12-24 19:05
Revised
2017-01-05 02:55
Second Decision
2017-02-15 18:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-02-17 10:06
Articles in Press
2017-02-17 10:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-03-02 16:34
Publish the Manuscript Online
2017-03-19 18:45
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Michael K Zheng, David Q Shih and Gary C Chen
Funding Agency and Grant Number
Corresponding Author Gary C Chen, MD, Comprehensive Digestive Institute of Nevada, 8530 West Sunset Road, Suite 230, Las Vegas, NV 89113, United States. garychen@nevadagastro.com
Key Words Biosimilar; Biologic; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Indication extrapolation; Interchangeability
Core Tip The expiration of patent protection for various biologics and increasing health care expenses has paved the way for biosimilars to enter the market. The introduction of biosimilars is expected to produce cost savings in the health care industry as well as provide patients with inflammatory bowel disease with wider access to treatment.
Publish Date 2017-03-19 18:45
Citation Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1932-1943
URL http://www.wjgnet.com/1007-9327/full/v23/i11/1932.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i11.1932
Full Article (PDF) WJG-23-1932.pdf
Full Article (Word) WJG-23-1932.doc
Manuscript File 31541-Review.docx
Answering Reviewers 31541-Answering reviewers.pdf
Audio Core Tip 31541-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 31541-Conflict-of-interest statement.pdf
Copyright License Agreement 31541-Copyright assignment.pdf
Peer-review Report 31541-Peer-review(s).pdf
Scientific Misconduct Check 31541-Scientific misconduct check.pdf
Scientific Editor Work List 31541-Scientific editor work list.pdf